UBS Group
GCTK icon

UBS Group’s GlucoTrack GCTK Stock Holding History

UBS Group’s Portfolio GCTK Stock Details GCTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$456 Buy
702
+583
+490% +$1.24K ﹤0.01% 9884
2025
Q4 		$461 Buy
119
+79
+198% +$469 ﹤0.01% 9951
2025
Q3 		$263 Buy
40
+39
+3,900% +$235 ﹤0.01% 9771
2025
Q2 		$6 Buy
+1
New +$9 ﹤0.01% 10169
2025
Q1 		– Hold
0
– – – 10402
2024
Q4 		– Sell
-3
Closed -$7.43K – 10094
2024
Q3 		$7.43K Sell
3
-2
-40% -$4.86K ﹤0.01% 7908
2024
Q2 		$12.2K Buy
+5
New +$15.1K ﹤0.01% 7607
2024
Q1 		– Sell
-1
Closed -$1.26K – 9564
2023
Q4 		$1.26K Buy
+1
New +$1.33K ﹤0.01% 8360
2023
Q3 		– Hold
0
– – – 9123
2023
Q2 		– Hold
0
– – – 8337
2022
Q1 		– Hold
0
– -$3K – 10472
2021
Q4 		– Hold
0
– – – 9655

Other funds holding GCTK

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
AF
Alerus Financial Grand Forks, North Dakota $2.02B AUM 26.03% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
NFSG
Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group's GCTK Position: Q1 2026 in Review

UBS Group increased its GlucoTrack (GCTK) stake by 490% in Q1 2026, buying an estimated $1.24K and bringing the position to 702 shares worth $456. The position accounts for ﹤0.01% of the portfolio, ranked #9884.

UBS Group first reported a position in GCTK in Q4 2023 and has held it in 7 quarters since. The position peaked at $12.2K in Q2 2024. 13 funds tracked by Wall St. Rank hold GCTK as of Q1 2026.

  • UBS Group held 702 shares of GlucoTrack worth $456 as of Q1 2026.
  • UBS Group bought 583 GlucoTrack shares in Q1 2026, an estimated $1.24K.
  • GlucoTrack made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #9884 holding.
  • UBS Group first reported a position in GlucoTrack in Q4 2023 and has held it in 7 quarters since.
  • UBS Group's GlucoTrack position peaked at $12.2K in Q2 2024.
  • 13 funds tracked by Wall St. Rank held GlucoTrack as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.